Prevention of aspirin-induced gastroduodenal damage: H. pylori infection eradication versus proton pump inhibitors or both

Digestive and Liver Disease

Volumn 36, Issue 10, 2004, Pages 655-657

  Lanas, A ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANTIBIOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; LANSOPRAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR; PROTON PUMP;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM INJURY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DUODENUM BLEEDING; DUODENUM ULCER; ERADICATION THERAPY; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; NOTE; PEPTIC ULCER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PETECHIA; PRIMARY PREVENTION; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; STOMACH EROSION; STOMACH HEMORRHAGE; STOMACH ULCER; SYSTEMATIC REVIEW; UPPER GASTROINTESTINAL BLEEDING; ANTIBIOTIC PROPHYLAXIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; PATHOLOGY; UPPER GASTROINTESTINAL TRACT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBIOTIC PROPHYLAXIS; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTIONS; HUMANS; PROTON PUMPS; RISK FACTORS; UPPER GASTROINTESTINAL TRACT;

EID: 16644383528     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2004.06.010     Document Type: Note

References (23)

1. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonier B, et al. Expert consensus document on the use of antiplatelet agents. Eur Heart J 2004;25:166-81.
2. Lanas A, Hirschowitz BI. Toxicity of NSAIDs in the stomach and duodenum. Eur J Gastroenterol Hepatol 1999;11:375-81.
3. Lanas AI. Current approaches to reducing gastrointestinal toxicity of low-dose aspirin. Am J Med 2001;110:70S-3S.
4. Simon B, Elsner H, Muller P. Protective effect of omeprazole against low-dose acetylsalicylic acid. Endoscopic controlled double-blind study in healthy subjects. Arzneimittelforschung 1995;45:701-3.
5. Muller P, Fuchs W, Simon B. Studies on the protective effect of lansoprazole on human gastric mucosa against low-dose acetylsalicylic acid. An endoscopic controlled double-blind study. Arzneimittelforschung 1997;47:758-60.
6. Kordecki H, Kurowski M, Kosik M, Pilecka D. Is Helicobacter pylori infection a risk or protective factor for mucosal lesions development in patients chronically treated with acetylsalicylic acid? J Physiol Pharmacol 1997;48:85-91.
7. Goldstein JL, Agrawal NM, Silverstein F, Verburg KM, Burr AM, Hubbard RC, et al. Influence of Helicobacter pylori infection and/or low-dose aspirin on gastroduodenal ulceration in patients treated with placebo, celecoxib or NSAIDs. Gastroenterology 1999;116:A174.
8. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999;117:17-25.
9. Yeomans N, Hawkey C, Lanas A, Naesdal J, Talley N, Thomson A. Prevalence of gastric and duodenal ulcers during treatment with low-dose aspirin. Gastroenterology 2002;122:A701.
10. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. Br Med J 2000;321:1183-7.
11. Serrano P, Lanas A, Arroyo MT, Ferreira U. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002;16:1945-53.
12. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995;310:827-30.
13. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996;348:1413-6.
14. Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000;343:834-9.
15. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Saínz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002;16:779-86.
16. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73.
17. Lai KC, Lam SK, Chu KM, Wong BCY, Hui WM, Hu WHC, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033-8.
18. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 2000;284:1247-55.
19. Donnelly MT, Goddard AF, Filipowicz B, Morant SV, Shield MJ, Hawkey CJ. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 2000;14:529-34.
20. Lanas A, Rodrigo L, Marquez JL, Bajador E, Perez-Roldan F, Cabrol J, et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol 2003;38:693-700.
21. Pilotto A, Franceschi M, Longo MG, Scarcelli C, Orsitto G, Perri F, et al. Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin. Dig Liver Dis 2004;36:666-70.
22. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-34.
23. Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359:9-13.